Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F] dopa PET

Journal of Neurology Neurosurgery and Psychiatry

Volumn 64, Issue 3, 1998, Pages 314-319

  Morrish, P K ^a,d   Rakshi, J S ^a   Bailey, D L ^a   Sawle, G V ^a,b   Brooks, D J ^a,c  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Parkinson's disease; PET; Preclinical period

Indexed keywords

DOPA; FLUORINE 18;

ADULT; AGED; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; DRUG UPTAKE; HUMAN; NORMAL HUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN;

AGED; CASE-CONTROL STUDIES; CAUDATE NUCLEUS; DIHYDROXYPHENYLALANINE; DISEASE PROGRESSION; HUMANS; LINEAR MODELS; MIDDLE AGED; PARKINSON DISEASE; PROSPECTIVE STUDIES; PUTAMEN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031898680     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.64.3.314     Document Type: Article

References (22)

1. Vingerhoets FJG, Snow BJ, Lee CS, et al. Longitudinal fluorodopa positron emission tomography studies of the evolution of idiopathic parkinsonism. Ann Neurol 1994;36:759-64.
2. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996;119:585-91.
3. Calne DB, Langston JW. Aetiology of Parkinson's disease. Lancet 1983;2:1457-9.
4. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-52.
5. Sawle GV, Colebatch JG, Shah A, et al. Striatal function in normal aging: implications for Parkinson's disease. Ann Neurol 1990;28:799-804.
6. Brooks DJ, Salmon EP, Mathias CJ, et al. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomie failure and Parkinson's disease, studied with PET. Brain 1990;113: 1539-52.
7. 18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Neurology 1994;44:1292-7.
8. Scheffe H. The analysis of variance. New York: Wiley, 1959; 221-60.
9. Bland JM, Altman DG. Calculating correlation coefficients with repeated observations: Part 2-correlation between subjects. BMJ 1995;310:633.
10. Koller WC. When does Parkinson's disease begin? Neurology 1992;42(suppl 4):27-31.
11. Vingerhoets FJ, Snow BJ, Schulzer M, et al. Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects. J Nucl Med 1994;35:18-24.
12. 18F]dopa PET study of the intrastriatal progression of Parkinson's disease. Brain 1996;119:2097-103.
13. Ichise M, Ballinger JR. Physiological modeling of PET data: quantitative conflict and challenge. J Nucl Med 1997;38: 1266.
14. Takikawa S, Dhawan V, Chaly T, et al. Input functions for 6-[Fluorine-18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations. J Nucl Med 1994;35:955-63.
15. 18F]dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 1995;59:597-600.
16. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:876-80.
17. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-301.
18. Leenders KL. Pathophysiology of movement disorders studied using PET. J Neurol Transm 1997;50:39-16.
19. 18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993;34: 324-30.
20. 18C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology 1997;48:1578-83.
21. Vingerhoets FJG, Schulzer M, Ruth TJ, et al. Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-dopa PET in Parkinson's disease. J Nucl Med 1996;37:421-6.
22. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-42.